Author

Norman Franke

Observed names: N Franke, N. Franke, Norman Anthony Franke

Institution: Princess Margaret Cancer Centre

Observed institutions: University Health Network, University of Toronto, Princess Margaret Cancer Centre, Canterbury District Health Board

OpenAlex ID: A5113861612

Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2

2019 · Linh T. Nguyen, Samuel D. Saibil, et al. · Cancer Immunology Immunotherapy · 143

PDF

Second Autologous Stem Cell Transplantation as Salvage Therapy for Multiple Myeloma: Impact on Progression-Free and Overall Survival

2011 · Victor H. Jimenez-Zepeda, Joseph Mikhael, et al. · Transplantation and Cellular Therapy · 117

Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance

2008 · D Kumar, A Humar, et al. · Bone Marrow Transplantation · 100

Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome

2003 · P N Mollee, A D Wechalekar, et al. · Bone Marrow Transplantation · 70

Efficacy, toxicity and mortality of autologous SCT in multiple myeloma patients with dialysis-dependent renal failure

2014 · R St Bernard, L Chodirker, et al. · Bone Marrow Transplantation · 57

Predictors of mortality in patients undergoing autologous hematopoietic cell transplantation admitted to the intensive care unit

2008 · M A Trinkaus, S E Lapinsky, et al. · Bone Marrow Transplantation · 53

High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin's lymphoma

2011 · N Puig, M Pintilie, et al. · Bone Marrow Transplantation · 37

Absolute lymphocyte count as predictor of overall survival for patients with multiple myeloma treated with single autologous stem cell transplant

2015 · Victor H. Jimenez-Zepeda, Donna E. Reece, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 32

Toxicity and survival outcomes of autologous stem cell transplant in multiple myeloma patients with renal insufficiency: an institutional comparison between two eras

2019 · Amanda Yan Li, Eshetu G. Atenafu, et al. · Bone Marrow Transplantation · 28

Transverse myelitis after anti‐CD19 directed CAR T cell therapy for relapsed large B cell lymphoma

2021 · Semira Sheikh, Sepideh Mokhtari, et al. · eJHaem · 24

PDF

Autologous stem cell transplant is an effective therapy for carefully selected patients with AL amyloidosis: experience of a single institution

2013 · Victor H. Jimenez‐Zepeda, Norman Franke, et al. · British Journal of Haematology · 23

Contamination of Bone Marrow Products with an Actinomycete ResemblingMicrobacteriumSpecies and Reinfusion into Autologous Stem Cell and Bone Marrow Transplant Recipients

2003 · Zahir Hirji, Ronnie Saragosa, et al. · Clinical Infectious Diseases · 19

Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin's lymphoma

2010 · N. Puig, M. Pintilie, et al. · Haematologica · 18

PDF

Oligoclonal and monoclonal bands after single autologous stem cell transplant in patients with multiple myeloma: impact on overall survival and progression-free survival

2013 · Victor H. Jimenez-Zepeda, Donna E. Reece, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 16

G-CSF-stimulated BM progenitor cells supplement suboptimal peripheral blood hematopoietic progenitor cell collections for auto transplantation

2008 · T Seshadri, K Al-Farsi, et al. · Bone Marrow Transplantation · 7

Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma: Improved Outcomes in Patients with Longer Disease Free Interval after First ASCT.

2007 · Joseph R. Mikhael, Sahar Zadeh, et al. · Blood · 7

Outcome after Second Autologous Stem Cell Transplantation as Salvage Therapy in Patients with Relapsed Multiple Myeloma.

2004 · Joseph R. Mikhael, Sara Samiee, et al. · Blood · 7

High-Dose Melphalan for AL Amyloidosis: The Importance of Case Selection to Improve Clinical Outcomes

2010 · Victor H Jimenez-Zepeda, Norman Franke, et al. · Blood · 6

Effect of minimal lymphodepletion prior to ACT with TBI-1301, NY-ESO-1 specific gene-engineered TCR-T cells, on clinical responses and CRS.

2019 · Marcus O. Butler, Sam Saibil, et al. · Journal of Clinical Oncology · 4

Second Autologous Stem Cell Transplant (ASCT) as Salvage Therapy in Patients with Relapsed Multiple Myeloma.

2009 · Joseph R. Mikhael, Sahar Zadeh, et al. · Blood · 3

A Phase Ii Study (Nct01883323) Evaluating the Infusion of Autologous Tumor-Infiltrating Lymphocytes (Til) and Low-Dose Interleukin-2 (Il-2) Therapy Following Non-Myeloablative Lymphodepletion Using Cyclophosphamide and Fludarabine in Patients with Metastatic Melanoma

2014 · L.T. Khoja, L. Nguyen, et al. · Annals of Oncology · 2

Monoclonal and Oligoclonal Bands After Single Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: Impact On Overall Survival and Progression-Free Survival

2012 · Victor Hugo Jimenez-Zepeda, Norman Franke, et al. · Blood · 2

Light Chain Deposition Disease: Impact of Stem Cell Tranplant on Hematological Response Achievement.

2010 · Victor H Jimenez-Zepeda, Norman Franke, et al. · Blood · 2

Second autologous stem cell transplantation as salvage therapy in patients with relapsed multiple myeloma: Improved outcomes in patients with longer disease free interval after first autologous stem cell transplantation

2006 · J. Mikhael, S. Samiee, et al. · Transplantation and Cellular Therapy · 2

PDF

Infectious Complications in the Outpatient and Inpatient Autologous Stem Cell Transplantation Setting for Patients with Multiple Myeloma. Princess Margaret Cancer Center Experience

2018 · Anna Nikonova, Christina Zeglinski, et al. · Blood · 1

Works count: 39

Citation count: 783

H-index: 14

I10-index: 14